Comorbidities in heart failure patients that predict cardiovascular readmissions within 100 days-An observational

Mia Scholten1, Jason Davidge1,2, Björn Agvall1,3

  • 1Center for Primary Health Care Research, Department of Clinical Sciences, Lund University, Lund, Sweden.

Plos One
|January 2, 2024
PubMed

Insights

Heart failure patients with atrial fibrillation, chronic kidney disease, or chronic obstructive pulmonary disease face higher readmission risks. However, these comorbidities alone do not fully predict readmission, indicating other factors are crucial.

Area of Science:

  • Cardiology
  • Public Health
  • Geriatrics

Background:

  • Heart failure (HF) is a common complication of cardiovascular diseases, often accompanied by comorbidities.
  • These comorbidities significantly impact HF patient outcomes and hospital readmissions.
  • Understanding comorbidity influence on HF readmission is vital for improving patient care.

Purpose of the Study:

  • To analyze the impact of specific comorbidities on cardiovascular-related readmission risk within 100 days post-discharge in HF patients.
  • To identify which comorbidities independently predict increased readmission rates.
  • To evaluate the predictive power of comorbidities for HF readmission.

Main Methods:

  • A population-based retrospective study of 5029 HF patients (2017-2019).
  • Competing risk regression and logistic regression analyzed 10 common comorbidities and their association with 100-day readmission.
  • Receiver operating characteristic (ROC) and area under curve (AUC) assessed model predictive performance.

Main Results:

  • Atrial fibrillation, COPD, CKD, PAD, and diabetes mellitus were initially associated with increased readmission HR.
  • After adjustment, only atrial fibrillation, CKD, and COPD remained significant predictors of readmission.
  • Logistic regression models incorporating comorbidities showed low AUC, indicating limited predictive power.

Conclusions:

  • Atrial fibrillation, chronic kidney disease, and chronic obstructive pulmonary disease are significantly linked to higher readmission risk in heart failure patients.
  • The low AUC from ROC analysis suggests that these comorbidities alone are insufficient predictors of readmission.
  • Further research should explore additional factors contributing to HF readmission risk.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
343